Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1154812 | 0.85 | GSK3B (0.57) | GSK3BKMT2ALMNAMEN1ALDH1A1 | |
| SCHEMBL1930256 | 0.81 | NPC1 (0.50) | GSK3BKMT2ALMNAMEN1ALDH1A1 | |
| SCHEMBL10432798 | 0.81 | MAPT (0.50) | GSK3BLMNAALDH1A1MAPTNPC1 | |
| SCHEMBL3866097 | 0.80 | MAPT (0.57) | KMT2ALMNAMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL28841619 | 0.77 | MMP1 (0.56) | GSK3BKMT2ALMNAMEN1ALDH1A1 | |
| SCHEMBL27460394 | 0.77 | GSK3B (0.54) | GSK3BKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL1155564 | 0.74 | ALDH1A1 (0.62) | GSK3BKMT2ALMNAMEN1ALDH1A1 | |
| SCHEMBL1712196 | 0.74 | GSK3B (0.48) | GSK3BKMT2ALMNAMEN1ALDH1A1 | |
| SCHEMBL9139245 | 0.73 | GSK3B (0.52) | GSK3BKMT2ALMNAMEN1ALDH1A1 | |
| SCHEMBL6328277 | 0.72 | MAPT (0.64) | GSK3BKMT2ALMNAMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3121176-A1 | 2,4-DIAMINOQUINAZOLINES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY | Families of Spinal Muscular Atrophy (US) | 2017-01-25 | — | — | EP | disclosed |
| EP-1765810-B1 | 2,4-DIAMINOQUINAZOLINES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2514748-B1 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20160152577-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2016-06-02 | — | — | US | disclosed |
| US-9067897-B2 | 2,4-Diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2015-06-30 | — | — | US | disclosed |
| EP-2514748-A1 | 2,4-diaminoquinazolines for spinal muscular atrophy | Families of Spinal Muscular Atrophy (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20110112118-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-05-12 | — | — | US | disclosed |
| US-7888366-B2 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-02-15 | — | — | US | disclosed |
| EP-1765810-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | Decode Chemistry, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-0841925-B1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005123724-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | DECODE CHEMISTRY, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-6482956-B2 | FOR THERAPY OF CARDIOVASCULAR, CEREBROVASCULAR, RESPIRATORY AND RENAL DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-11-19 | — | — | US | disclosed |
| US-20020072614-A1 | Endothelin receptor antagonists | LUENGO JUAN IGNACIO (US) | 2002-06-13 | — | — | US | disclosed |
| US-6353116-B1 | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-03-05 | — | — | US | disclosed |
| EP-0841925-A4 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6096897-A | NOVEL 1,2,3-TRIAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
| US-5969151-A | PYRAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| US-5958968-A | CARDIOVASCULAR DISORDERS; KIDNEY DIEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0841925-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997004772-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112118-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | SMN1; SMN2, MUSK, MYO3B | GSK3B 2837/4885KMT2A 91/4885LMNA 523/4885 |
| US-20160152577-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | SMN1; SMN2, MUSK, MYO3B | GSK3B 2837/4885KMT2A 91/4885LMNA 523/4885 |
| US-20020072614-A1 | Endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | GSK3B 4124/4885KMT2A 4412/4885LMNA 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.